28 results on '"Davidson, Michael H."'
Search Results
2. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
- Author
-
Benes, Lane B., Bassi, Nikhil S., and Davidson, Michael H.
- Subjects
DYSLIPIDEMIA ,CARBOXYLIC acids ,THERAPEUTIC use of omega-3 fatty acids ,STATINS (Cardiovascular agents) ,COMBINATION drug therapy ,THERAPEUTICS - Abstract
The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in part because of triglyceride-rich lipoprotein cholesterol. Several large trials have failed to show benefit with non-statin cholesterol-lowering medications in the reduction of cardiovascular events. Yet, subgroup analyses showed a benefit in those with hypertriglyceridemia and lower high-density lipoprotein cholesterol level, a high-risk pattern of dyslipidemia. This review discusses the benefits of omega-3 carboxylic acids, a recently approved formulation of omega-3 fatty acid with enhanced bioavailability, in the treatment of dyslipidemia both as monotherapy and combination therapy with a statin. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
- Author
-
Davidson, Michael H, Phillips, Alyssa K, Kling, Douglas, and Maki, Kevin C
- Subjects
THERAPEUTIC use of omega-3 fatty acids ,CARBOXYLIC acids ,HYPERTRIGLYCERIDEMIA ,HYPERTRIGLYCERIDEMIA treatment ,OVERWEIGHT persons ,DYSLIPIDEMIA ,PATIENTS ,THERAPEUTICS - Abstract
The incidence of hypertriglyceridemia has grown alongside that of obesity. Statin therapy has been widely recommended for the treatment of dyslipidemias. Omega-3 (OM3) fatty acid concentrates are commonly prescribed concurrently with statins in patients with persistent hypertriglyceridemia for additional lowering of triglyceride and non-HDL cholesterol. The bioavailability of currently available OM3 ethyl ester drugs is limited by their need for hydrolysis by pancreatic lipases, largely stimulated by dietary fat, prior to intestinal absorption. This review will discuss the chemistry, pharmacokinetics and clinical efficacy of a novel OM3 carboxylic acid drug that provides polyunsaturated docosahexaenoic and eicosapentaenoic acids in the free fatty acid form, which is readily absorbed by the intestine. This drug was approved in May 2014 as an adjunct to diet to reduce triglyceride levels in adults with severe (≥500 mg/dl) hypertriglyceridemia. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
- Author
-
Ballantyne, Christie M., Davidson, Michael H., MacDougall, Diane E., Bays, Harold E., DiCarlo, Lorenzo A., Rosenberg, Noah L., Margulies, Janice, and Newton, Roger S.
- Subjects
- *
MEDICATION safety , *DRUG efficacy , *ADENOSINE triphosphate , *LYASES , *ADENOSINE monophosphate , *HYPERCHOLESTEREMIA , *PROTEIN kinases , *RANDOMIZED controlled trials , *PATIENTS , *THERAPEUTICS - Abstract
Objectives: The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. Background: ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemia and other cardiometabolic risk factors. Methods: This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated patients (n = 177) with elevated low-density lipoprotein cholesterol (LDL-C) (130 to 220 mg/dl), who were stratified by baseline triglycerides (not elevated [<150 mg/dl] or elevated [150–<400 mg/dl]) and randomized to receive 40, 80, or 120 mg of ETC-1002 or placebo once daily for 12 weeks. Outcomes included changes in LDL-C (primary endpoint), other lipids, and cardiometabolic risk factors; and safety. Results: ETC-1002 40, 80, and 120 mg lowered least-squares mean ± SE LDL-C levels by 17.9 ± 2.2%, 25.0 ± 2.1%, and 26.6 ± 2.2%, respectively, versus a reduction of 2.1 ± 2.2% with placebo (all, p < 0.0001); LDL-C lowering was similar between the subgroups with nonelevated and elevated triglycerides. ETC-1002 also lowered non–high-density lipoprotein cholesterol (non–HDL-C), apolipoprotein B, and LDL particle number (all, p < 0.0001) in a dose-dependent manner; HDL-C and triglyceride levels were relatively unchanged. Post-hoc analyses suggest that ETC-1002 may have favorable effects on other cardiometabolic risk factors. The ETC-1002 and placebo groups did not demonstrate clinically meaningful differences in adverse events or other safety assessments. Conclusions: ETC-1002 significantly lowered LDL-C levels up to 27% across a broad range of baseline triglycerides and was generally safe and well tolerated. ETC-1002 has a novel mechanism of action and may be useful for reducing LDL-C. (A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides; NCT01262638) [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.
- Author
-
Freed, Benjamin H., Narang, Akhil, Bhave, Nicole M., Czobor, Peter, Mor-Avi, Victor, Zaran, Emily R., Turner, Kristen M., Cavanaugh, Kevin P., Chandra, Sonal, Tanaka, Sara M., Davidson, Michael H., Lang, Roberto M., and Patel, Amit R.
- Subjects
MAGNETIC resonance imaging evaluation ,VASODILATORS ,CONFIDENCE intervals ,CORONARY disease ,FISHER exact test ,LONGITUDINAL method ,PROBABILITY theory ,RESEARCH funding ,STATISTICS ,T-test (Statistics) ,U-statistics ,DATA analysis ,DATA analysis software ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,LOG-rank test ,PROGNOSIS ,THERAPEUTICS - Abstract
Background Regadenoson is a vasodilator stress agent that selectively activates the A2A receptor. Compared to adenosine, regadenoson is easier to administer and results in fewer side effects. Although extensively studied in patients undergoing nuclear perfusion imaging (MPI), its use for perfusion cardiovascular magnetic resonance (CMR) is not well described. The aim of this study was to determine the prognostic value of a normal regadenoson perfusion CMR in patients with known or suspected coronary artery disease. Methods Patients with known or suspected coronary artery disease were prospectively enrolled to receive perfusion CMR (Philips 1.5 T) with regadenoson. Three short-axis slices of the left ventricle (LV) were obtained during first pass of contrast using a hybrid GRE-EPI pulse sequence (0.075 mmol/kg Gadolinium-DTPA-BMA at 4 ml/sec). Imaging was performed 1 minute after injection of regadenoson (0.4 mg) and repeated 15 minutes after reversal of hyperemia with aminophylline (125 mg). Perfusion defects were documented if they persisted for ≥2 frames after peak enhancement of the LV cavity. CMR was considered abnormal if there was a resting wall motion abnormality, decreased LVEF (<40%), presence of LGE, or the presence of a perfusion defect during hyperemia. All patients were followed for a minimum of 1 year for major adverse cardiovascular event (MACE) defined as coronary revascularization, non-fatal myocardial infarction, and cardiovascular death. Results 149 patients were included in the final analysis. Perfusion defects were noted in 43/149 (29%) patients; 59/149 (40%) had any abnormality on CMR. During the mean follow-up period of 24 ± 9 months, 17/149 (11.4%) patients experienced MACE. The separation in the survival distributions for those with perfusion defects and those without perfusion defects was highly significant (log-rank p = 0.0001). When the absence of perfusion defects was added to the absence of other resting CMR abnormalities, the negative predictive value improved from 96% to 99%. Conclusion Regadenoson perfusion CMR provides high confidence for excellent prognosis in patients with normal perfusion. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic ...
- Author
-
Davidson, Michael H., Johnson, Judith, Rooney, Michael W., Kyle, Michael L., and Kling, Douglas F.
- Subjects
BIOAVAILABILITY ,HYPERTRIGLYCERIDEMIA treatment ,EICOSAPENTAENOIC acid ,DOCOSAHEXAENOIC acid ,LOW-fat diet ,PHARMACOKINETICS ,PHYSIOLOGICAL effects of fatty acids ,OVERWEIGHT persons ,THERAPEUTICS ,OMEGA-3 fatty acids ,TRIGLYCERIDES ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics - Abstract
Background: Omega-3 (OM-3) fatty acid products are indicated for the treatment of severe hypertriglyceridemia; however, the omega-3-acid ethyl ester (OM-3 EE) formulations require significant pancreatic lipase stimulation with high-fat meals for adequate intestinal absorption of the metabolites eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). A novel omega-3 free fatty acid (OM-3 FFA) formulation (Epanova
® , Omthera Pharmaceuticals Inc., Princeton, NJ) was developed to maximize EPA and DHA bioavailability during a low-fat diet. Objective: To compare the relative bioavailability of EPA and DHA from single 4-gram doses of OM-3 FFA and a prescription OM-3 EE (Lovaza® , GlaxoSmithKline, Research Triangle Park, NC). Methods: This was a randomized, open-label, single dose, 4-way crossover, bioavailability study of OM-3 FFA and OM-3 EE administered during periods of low-fat and high-fat consumption to 54 overweight adults. Bioavailability was determined by the ln-transformed area under the plasma concentration versus time curve (AUC0-t ) during a 24-hour interval for EPA and DHA (baseline-adjusted). Results: The baseline-adjusted AUC0-t for total EPA + DHA during the low-fat period was 4.0-fold greater with OM-3 FFA compared with OM-3 EE (2650.2 vs 662.0 nmol·h/mL, respectively; P < .0001). During the high-fat period, AUC0-t for OM-3 FFA was approximately 1.3-fold greater than OM-3 EE (P < .0001). During the low-fat period, 30 of 51 (58.8%) subjects dosed with OM-3 FFA maintained an AUC0-t that was ≥50% of the respective high-fat AUC0-t in contrast to only 3 of 50 (6.0%) subjects dosed with OM-3 EE. Conclusions: During a low-fat consumption period, the OM-3 FFA formulation provided dramatically improved bioavailability over the OM-3 EE formulation in overweight subjects. These findings offer a potential therapeutic advantage of the OM-3 FFA formulation for the treatment of severe hypertriglyceridemia as these patients are expected to adhere to a low-fat diet. [Copyright &y& Elsevier]- Published
- 2012
- Full Text
- View/download PDF
7. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies.
- Author
-
Roth, Eli M., Rosenson, Robert S., Jones, Peter H., Davidson, Michael H., Kelly, Maureen T., Setze, Carolyn M., Lele, Aditya, and Thakker, Kamlesh
- Subjects
DYSLIPIDEMIA ,FENOFIBRATE ,ROSUVASTATIN ,ANTILIPEMIC agents ,DRUG efficacy ,LITERATURE reviews ,THERAPEUTICS ,DRUG therapy for hyperlipidemia ,ANTICHOLESTEREMIC agents ,HYPERLIPIDEMIA ,CARDIOVASCULAR diseases risk factors ,COMBINATION drug therapy ,LIPIDS ,STATISTICS ,DATA analysis ,DESCRIPTIVE statistics ,PREVENTION - Abstract
Background: Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels. Objective: To evaluate attainment of goal/desirable levels of lipids/lipoproteins after 12-week treatment with combination rosuvastatin + fenofibric acid versus rosuvastatin monotherapy. Methods: This was a post hoc analysis of patients with mixed dyslipidemia who enrolled in one of two randomized controlled trials, and were treated (N = 2066) with rosuvastatin (5, 10, or 20 mg), fenofibric acid 135 mg, or rosuvastatin + fenofibric acid for 12 weeks. Data were pooled across doses of rosuvastatin as monotherapy and combination therapy. Results: Compared with rosuvastatin monotherapy, combination therapy had comparable effects in achieving risk-stratified LDL-C goals; however, measures of total atherogenic burden were improved because significantly greater percentages of patients attained non-HDL-C goal in high- (62.9% vs 50.4%, P = .006) and moderate-risk groups (87.6% vs 80.4%, P = .016) and apolipoprotein B (ApoB) <90 mg/dL in high-risk group (59.8% vs 43.8%, P < .001). In the overall population, more patients treated with the combination therapy achieved desirable levels of HDL-C >40/50 mg/dL in men/women (P < .001), triglycerides <150 mg/dL (P < .001), and ApoB <90 mg/dL (P < .001), compared with rosuvastatin monotherapy. Furthermore, combination therapy resulted in significantly greater percentages of patients achieving simultaneous specified levels of LDL-C + non-HDL-C (P < .015); LDL-C + HDL-C + TG (P < .001); and LDL-C + HDL-C + triglycerides + non-HDL-C + ApoB (P < .001), compared with rosuvastatin monotherapy. Conclusion: Rosuvastatin + fenofibric acid may be more efficacious than rosuvastatin alone in patients with mixed dyslipidemia. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L).
- Author
-
Ballantyne, Christie M., Davidson, Michael H., Setze, Carolyn M., and Kelly, Maureen T.
- Subjects
STATINS (Cardiovascular agents) ,DYSLIPIDEMIA ,C-reactive protein ,CARDIOVASCULAR diseases risk factors ,BIOMARKERS ,THERAPEUTICS ,PATIENTS - Abstract
Background: Elevated levels of high-sensitivity C-reactive protein (hsCRP) correlate with an increased risk for cardiovascular events. Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia. Objective: To characterize the treatment effects of rosuvastatin and fenofibric acid combination therapy compared with individual monotherapies in mixed dyslipidemic patients with baseline hsCRP ≥2 mg/L versus <2 mg/L and to determine the effects of long-term treatment with rosuvastatin and fenofibric acid combination therapy on hsCRP and other lipids for patients with hsCRP ≥2 mg/L after treatment with rosuvastatin monotherapy. Methods: Data for the post hoc analysis were derived from two 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; rosuvastatin 5, 10, 20, or 40 mg; or rosuvastatin 5, 10, or 20 mg and fenofibric acid 135 mg in the controlled studies; and with rosuvastatin 20 mg and fenofibric acid 135 mg in the extension study. Results: In this analysis, 65% (1416/2182) of patients had pretreatment baseline hsCRP ≥2 mg/L. Among all treatment groups, larger decreases in hsCRP were observed in patients with greater baseline hsCRP; however, improvements in other lipids/apolipoprotein were comparable between the baseline hsCRP categories. Among patients with high hsCRP (≥2 mg/L) remaining after 12 weeks of rosuvastatin 10, 20, or 40 mg monotherapy, hsCRP was reduced by ∼36% after switching to rosuvastatin 20 mg and fenofibric acid 135 mg for up to 52 weeks, and ∼36% of patients shifted from hsCRP ≥2 mg/L to <2 mg/L. Conclusions: Combination therapy with rosuvastatin and fenofibric acid may be effective for improving the inflammatory biomarker, hsCRP as well as other lipid abnormalities in patients with mixed dyslipidemia and high hsCRP. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia.
- Author
-
Davidson, Michael H.
- Subjects
HYPERCHOLESTEREMIA in children ,LOW density lipoproteins ,SEQUESTRATION (Chemistry) ,BILE acids ,ANTILIPEMIC agents ,DRUG efficacy ,SYSTEMATIC reviews ,DRUG tolerance ,DRUG therapy ,THERAPEUTICS - Abstract
Abstract: Familial hypercholesterolemia, which arises as a result of a mutation in the low-density lipoprotein (LDL) receptor gene, is characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), regardless of dietary and lifestyle modifications. Pharmacological therapy is often required to adequately control the elevated LDL-C levels associated with familial hypercholesterolemia. However, children with this genetic condition present many challenges for physicians, who must weigh the benefits of lipid-lowering therapy against the risks associated with the various treatment options. Furthermore, because familial hypercholesterolemia is a chronic condition, children will likely require long-term lipid-lowering therapy. As such, the potential effect of pharmacological treatment on development is of paramount importance in this population. Bile acid sequestrants represent a unique treatment option for children with familial hypercholesterolemia in that these agents are not systemically absorbed but rather exert their lipid-lowering effects via binding to bile acids within the gastrointestinal tract. A literature search was performed to identify clinical data related to the use of bile acid sequestrant therapy in children (<18 years of age) with familial hypercholesterolemia. Studies published in English between 1990 and December 2010 that were retrieved from MEDLINE and EMBASE were included in this systematic review. In total, five clinical studies were identified that evaluated bile acid sequestrant monotherapy, whereas two studies were identified that evaluated combination therapy with a bile acid sequestrant and low-dose statin. This review summarizes the clinical data regarding the efficacy and safety of bile acid sequestrants in this specialized population. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study
- Author
-
Davidson, Michael H., Rooney, Michael W., Drucker, Joan, Eugene Griffin, H., Oosman, Sonia, and Beckert, Michael
- Subjects
- *
STATINS (Cardiovascular agents) , *FENOFIBRATE , *CLINICAL drug trials , *LIPID metabolism disorders , *DRUG administration , *ANTILIPEMIC agents , *THERAPEUTICS - Abstract
Background: Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed. Objective: This study evaluates a new FDC tablet of atorvastatin 40 mg and fenofibrate 100 mg. Methods: This was a 12-week, multicenter, doubleblind, randomized, parallel-group Phase IIb study. Adults with dyslipidemia (non−HDL-C >130 mg/dL and triglycerides [TG] ≥150 but ≤500 mg/dL) were randomly assigned in a 1:1:1 ratio to receive the FDC, atorvastatin 40 mg, or fenofibrate 145 mg for 12 weeks. Study medication was taken once daily in the evening, without regard to meals. Patients attended follow-up visits after 4, 8, and 12 weeks of the double-blind treatment. The primary efficacy end points were the mean percentage changes from baseline to the final visit (week 12) in non−HDL-C, HDL-C, and TG. Secondary variables were LDL-C, VLDL-C particle concentration, total cholesterol, apolipoprotein B, lipoprotein (a), high-sensitivity C-reactive protein, fibrinogen, homocysteine, creatinine, myeloperoxidase, and lipoproteinassociated phospholipase A2. Tolerability was assessed by adverse events, laboratory parameters, vital signs, physical examinations, and ECGs. Results: Patients (n = 220) were aged 26 to 87 years; 115 (52.3%) were men and 105 (47.7%) were women; 189 (85.9%) were white, 17 (7.7%) were black, and 15 (6.8%) were Hispanic or Latino; and mean (SD) weight was 200.5 (40.85) lb (range, 103.5–367.4 lb). Previous treatments were statins (25.9% [57/220]), fibrates (1.8% [4/220]), and dietary supplements (25.5% [56/220]); 57.7% (127/220) of patients were treatment naive. Use of the FDC was associated with an improvement in non−HDL-C (−44.8%) that was significantly greater than with fenofibrate monotherapy (−16.1%; P < 0.001) but was not significantly different from that with atorvastatin monotherapy (−40.2%; P = NS). HDL-C increased significantly more in the FDC group (19.7%) than with atorvastatin (6.5%; P < 0.001) but was not significantly different from fenofibrate (18.2%; P = NS). TG lowering in the FDC group (−49.1%) was significantly greater than with both atorvastatin (−28.9%; P < 0.001) and fenofibrate (−27.8%; P = 0.001). LDL-C lowering in the FDC group (−42.3%) was significantly greater than with fenofibrate (−13.9%; P < 0.001) but not significantly different from atorvastatin (−43.1%; P = NS). The FDC had either comparable or significantly greater improvements in other lipid variables and multiple secondary variables. The FDC was generally well tolerated; the tolerability profile was consistent with those of atorvastatin and fenofibrate monotherapies. Treatment-emergent adverse events (ie, those occurring after the first dose of study medication) were recorded in 43 of 73 patients (58.9%) for the FDC, 49 of 74 (66.2%) for atorvastatin, and 48 of 73 (65.8%) for fenofibrate. Conclusions: In this 12-week study, patients with dyslipidemia treated with the 40/100-mg atorvastatin/ fenofibrate FDC had a significantly greater reduction in TG than those treated with atorvastatin 40 mg or higher-dose fenofibrate 145 mg. Treatment with the FDC was also associated with a significantly greater reduction in non−HDL-C compared with fenofibrate alone and a greater increase in HDL-C compared with atorvastatin alone. All treatments were generally well tolerated. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
11. Effects of Consumption of Pomegranate Juice on Carotid Intima–Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease
- Author
-
Davidson, Michael H., Maki, Kevin C., Dicklin, Mary R., Feinstein, Steven B., Witchger, MarySue, Bell, Marjorie, McGuire, Darren K., Provost, Jean-Claude, Liker, Harley, and Aviram, Michael
- Subjects
- *
POMEGRANATE , *FRUIT juices -- Therapeutic use , *CORONARY heart disease risk factors , *HIGH density lipoproteins , *CLINICAL trials , *BLOOD lipids , *TRIGLYCERIDES , *THERAPEUTICS ,CAROTID artery abnormalities - Abstract
This randomized, double-blind, parallel trial assessed the influence of pomegranate juice consumption on anterior and posterior carotid intima–media thickness (CIMT) progression rates in subjects at moderate risk for coronary heart disease. Subjects were men (45 to 74 years old) and women (55 to 74 years old) with ≥1 major coronary heart disease risk factor and baseline posterior wall CIMT 0.7 to 2.0 mm, without significant stenosis. Participants consumed 240 ml/day of pomegranate juice (n = 146) or a control beverage (n = 143) for up to 18 months. No significant difference in overall CIMT progression rate was observed between pomegranate juice and control treatments. In exploratory analyses, in subjects in the most adverse tertiles for baseline serum lipid peroxides, triglycerides (TGs), high-density lipoprotein (HDL) cholesterol, TGs/HDL cholesterol, total cholesterol/HDL cholesterol, and apolipoprotein-B100, those in the pomegranate juice group had significantly less anterior wall and/or composite CIMT progression versus control subjects. In conclusion, these results suggest that in subjects at moderate coronary heart disease risk, pomegranate juice consumption had no significant effect on overall CIMT progression rate but may have slowed CIMT progression in subjects with increased oxidative stress and disturbances in the TG-rich lipoprotein/HDL axis. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
12. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study
- Author
-
Jones, Peter H., Davidson, Michael H., Kashyap, Moti L., Kelly, Maureen T., Buttler, Susan M., Setze, Carolyn M., Sleep, Darryl J., and Stolzenbach, James C.
- Subjects
- *
DRUG efficacy , *MEDICATION safety , *STATINS (Cardiovascular agents) , *LIPID metabolism disorders , *DRUG dosage , *RANDOMIZED controlled trials , *THERAPEUTICS - Abstract
Abstract: Objective: To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia. Methods: In a phase 3, multicenter, randomized, double-blind, active-controlled study, a total of 1445 patients with LDL-C≥130mg/dL, TG≥150mg/dL, and HDL-C<40mg/dL (<50mg/dL for women) were randomized to either ABT-335 (135mg), rosuvastatin (10, 20, or 40mg), or ABT-335+rosuvastatin 10 or 20mg, and treated for 12 weeks. The primary efficacy comparisons were mean percent change in HDL-C and TG (ABT-335+rosuvastatin vs. corresponding dose of rosuvastatin), and LDL-C (ABT-335+rosuvastatin vs. ABT-335). Results: Combination therapy with ABT-335+rosuvastatin 10mg resulted in significantly (p <0.001) greater improvements in HDL-C (20.3% vs. 8.5%) and TG (−47.1% vs. −24.4%) compared to rosuvastatin 10mg; and LDL-C (−37.2% vs. −6.5%) compared to ABT-335. Similarly, significantly (p <0.001) greater improvements were observed with ABT-335+rosuvastatin 20mg in HDL-C (19.0% vs. 10.3%) and TG (−42.9% vs. −25.6%) compared to rosuvastatin 20mg; and LDL-C (−38.8% vs. −6.5%) compared to ABT-335 monotherapy. Greater improvements in multiple secondary endpoints were noted with combination therapy compared to prespecified monotherapies. Both combination therapy doses were generally well tolerated, with a safety profile consistent with ABT-335 and rosuvastatin monotherapies. No rhabdomyolysis or unexpected hepatic, renal, or muscle safety signals were identified. Conclusion: In patients with mixed dyslipidemia, combination therapy with ABT-335+rosuvastatin resulted in more effective control of multiple lipid parameters than either monotherapy alone, with a safety profile similar to both monotherapies. This combination may be an appropriate therapeutic option to treat mixed dyslipidemia. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
13. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.
- Author
-
Jones, Peter H., Davidson, Michael H., Goldberg, Anne C., Pepine, Carl J., Kelly, Maureen T., Buttler, Susan M., Setze, Carolyn M., Lele, Aditya, Sleep, Darryl J., and Stolzenbach, James C.
- Subjects
THERAPEUTICS ,CHOLESTEROL ,ISOPENTENOIDS ,TRIGLYCERIDES - Abstract
Background: Patients with mixed dyslipidemia often require combination therapy to manage multiple lipid abnormalities. Objective: To evaluate fenofibric acid in combination with a statin across three studies of patients with mixed dyslipidemia. Methods: As prospectively planned, data were pooled from three randomized, double-blind, phase 3 studies of patients with low-density lipoprotein cholesterol (LDL-C) ≥130mg/dL, triglycerides (TG) ≥150mg/dL, and high-density lipoprotein cholesterol (HDL-C) <40mg/dL (men) or <50mg/dL (women). A total of 2715 patients were randomly assigned to 12-week treatment with fenofibric acid 135mg monotherapy; low-, moderate-, or high-dose statin (rosuvastatin, simvastatin, or atorvastatin, depending on study) monotherapy; or fenofibric acid + low- or moderate-dose statin. The primary efficacy comparisons were mean percent change in HDL-C and TG (combination therapy vs. statin) and LDL-C (combination therapy vs. fenofibric acid). Results: Fenofibric acid + low-dose statin increased HDL-C (18.1% vs. 7.4%) and reduced TG (−43.9% vs. −16.8%) versus low-dose statin monotherapy and reduced LDL-C (−33.1% vs. −5.1%) versus fenofibric acid monotherapy (P <.001 for all). Fenofibric acid + moderate-dose statin increased HDL-C (17.5% vs. 8.7%) and reduced TG (−42.0% vs. −23.7%) versus moderate-dose statin monotherapy and reduced LDL-C (−34.6% vs. −5.1%) versus fenofibric acid monotherapy (P <.001 for all). Combination therapy was generally well tolerated, and safety profiles were similar to monotherapies. No rhabdomyolysis was reported. Conclusion: In patients with mixed dyslipidemia, combination therapy simultaneously improved multiple lipid abnormalities more effectively than fenofibric acid or statin monotherapies. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
14. High-dose statin therapy: Benefits and safety in aggressive lipid lowering.
- Author
-
Toth, Peter R. and Davidson, Michael H.
- Subjects
- *
LIPID metabolism , *STATINS (Cardiovascular agents) , *BLOOD lipids , *THERAPEUTICS , *ENZYME inhibitors , *PRAVASTATIN , *CHEMICAL inhibitors , *ANTIFIBRINOLYTIC agents - Abstract
The article outlines the implication of high-dose statin therapy in lowering the aggressive lipids of dyslipidemia patients in Illinois. Eventhough there are clear benefits obtained in lipid-modifying drugs, current management of dyslipidemia remains suboptimal. More often, patients failed to achieve guideline-recommended lipid goals due to the result of either no or suboptimal statin therapy. Research shows that the level of lipid lowering can be obtained safely in most patients by using a high-dose statin monotherapy.
- Published
- 2008
15. Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia: The OCEANS Study.
- Author
-
Karas, Richard H., Kashyap, Moti L., Knopp, Robert H., Keller, Laurence H., Bajorunas, Daiva R., and Davidson, Michael H.
- Subjects
CARDIOVASCULAR agents ,NIACIN ,STATINS (Cardiovascular agents) ,ISOPENTENOIDS ,LIPOPROTEINS ,TRIGLYCERIDES ,THERAPEUTICS - Abstract
Introduction: High-dose HMG-CoA reductase inhibitors (statins) fail to prevent approximately two-thirds of cardiovascular events. This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy. Methods: The OCEANS study (Open-label evaluation of the safety and efficacy of a Combination of niacin ER and simvAstatin in patieNts with dySlipidemia; ClinicalTrials.gov identifier: NCT00080275) evaluated the safety and efficacy of a combination of niacin extended release and simvastatin (NER/S; SIMCOR®) over 52 weeks in 520 patients with mixed dyslipidemia. After a ≥4-week run-in phase of diet modification and simvastatin 40 mg/day, median baseline values (mg/dL) were: non-HDL-C = 141, low-density lipoproteincholesterol (LDL-C) = 110, HDL-C = 45, and triglyceride = 151. Patients were randomized to an 8- or 12-week niacin titration scheme to a maximum NER/S dosage of 2000/40 mg/day. Results: Differences between titration groups in tolerability, safety, and efficacy were minimal; therefore, all results are for pooled titration groups. The safety of NER/S was consistent with the safety profile of each individual component. Treatment with NER/S was well tolerated: 71% of patients experienced flushing and 92% of flushing episodes were mild or moderate in intensity. Overall, 61% of patients experienced flushing episodes that were rated as mild or moderate in intensity. Flushing decreased over time: <40% of those who had flushing during titration experienced flushing during the final 12 weeks. A total of 20% of patients discontinued treatment because of a treatment-related adverse event, including 7% who discontinued because of flushing. Median changes from baseline (following the simvastatin 40 mg/day run-in phase) to 24 weeks were: non-HDL-C = -27.3%, LDL-C = -25.0%, HDL-C = +23.9%, and triglycerides = -35.9% (all p < 0.0001 vs baseline). In lipidtreatment- naive patients, NER/S 2000/40 mg/day decreased non-HDL-C, LDL-C, and triglycerides by approximately 50% and increased HDL-C by approximately 25% when week-24 lipid values were compared with lipid values obtained prior to the simvastatin 40 mg/day run-in. All three therapeutic lipid targets (LDL-C [riskadjusted goal], HDL-C ≥40 mg/dL, and triglycerides <150 mg/dL) were achieved concurrently by 65% of patients treated with NER/S. Conclusion: Treatment with NER/S 2000/40 mg/day is well tolerated, has no unanticipated adverse events, and provides additional, clinically relevant improvements in multiple lipid parameters beyond statin monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Safety of Aggressive Lipid Management
- Author
-
Davidson, Michael H. and Robinson, Jennifer G.
- Subjects
- *
CORONARY disease , *HEART diseases , *THERAPEUTICS , *STATINS (Cardiovascular agents) , *CLINICAL trials - Abstract
Data from recent clinical trials of high- versus moderate-dose statin therapy support the recommendation to achieve a low-density lipoprotein (LDL) <100 mg/dl in high-risk patients and reveal that many patients will require a high-dose statin to achieve this goal. Overall, low rates of serious musculoskeletal (<0.6%) and hepatic (<1.3%) toxicity have been observed with high-dose statin therapy. In the long-term trials, atorvastatin 80 mg had higher rates of persistent transaminase elevations but rates of myopathy and rhabdomyolysis similar to lower doses of statins. The rate of myopathy and rhabdomyolysis for simvastatin 80 mg, although still low, was about 4× higher than for atorvastatin 80 mg and lower doses of statin. A similar margin of safety would be expected in properly selected patients with characteristics similar to those who participated in the clinical trials. High-dose statin therapy or combination therapy will be required for the large majority of very high-risk patients to achieve the optional LDL goal of <70 mg/dl. While the combination of ezetimibe, bile-acid sequestering agents, niacin, and fenofibrate with moderate dose statins appears to be reasonably safe, the long-term safety of combination with high-dose statins remains to be established. In order to optimize patient outcomes, clinicians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or glomerular filtration rate, which predict muscle and hepatic statin toxicity. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
17. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations
- Author
-
Davidson, Michael H., Maki, Kevin C., Pearson, Thomas A., Pasternak, Richard C., Deedwania, Prakash C., McKenney, James M., Fonarow, Gregg C., Maron, David J., Ansell, Benjamin J., Clark, Luther T., and Ballantyne, Christie M.
- Subjects
- *
ISOPENTENOIDS , *STEROLS , *CHOLESTEROL , *HEART diseases , *THERAPEUTICS - Abstract
The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, ≥2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations ≥200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
18. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
- Author
-
Insull, William, Davidson, Michael H., Kulkarni, Pandurang M., Siddhanti, Suresh, Ciaccia, Angelina V., and Keech, Cheryl A.
- Subjects
THERAPEUTICS ,CHOLESTEROL ,PLACEBOS ,LIVER disease diagnosis - Abstract
Abstract: Raloxifene and low-dose simvastatin can each reduce low-density lipoprotein (LDL) cholesterol without affecting high-density lipoprotein (HDL) cholesterol and triglycerides. The objective of this double-blind, 12-week study is to determine whether raloxifene and simvastatin coadministration gives added benefit beyond either monotherapy in affecting fasting lipoproteins and apolipoproteins. Ninety-five postmenopausal women with moderately elevated LDL cholesterol (mean, 146 mg/dL) were randomized to placebo, raloxifene 60 mg/d, simvastatin 10 mg/d, or raloxifene 60 mg/d coadministered with simvastatin 10 mg/d. Raloxifene, simvastatin, and coadministration therapy reduced mean LDL cholesterol by 10.5%, 23.3%, and 31.0% from baseline, respectively (P < .003 vs baseline; P < .02 vs placebo), and mean apolipoprotein B by 10.4%, 24.2%, and 30.0% from baseline, respectively (P < .003 vs baseline; P < .02 vs placebo). Each active treatment decreased non-HDL cholesterol compared with placebo (P < .01). Coadministration treatment was more effective than either monotherapy in reducing LDL cholesterol (P < .05). Coadministration treatment reduced mean apolipoprotein B (P < .001) and non-HDL cholesterol (P < .001) when compared with raloxifene, but was not significantly different when compared with simvastatin. Coadministration therapy increased HDL cholesterol and apolipoprotein A1 levels compared with placebo (P < .02). No significant effect on triglycerides, very low density lipoprotein cholesterol, and lipoprotein (a) occurred with any active treatment. Raloxifene, simvastatin, and the coadministration therapy were generally well tolerated with clinical adverse effects similar to placebo. No woman had clinically significant elevated liver function tests requiring drug discontinuation. Further data on safety and lipid-lowering effects are needed before raloxifene and statin coadministration may be considered as therapeutic interventions for treating postmenopausal women to achieve National Cholesterol Education Program–Adult Treatment Panel III treatment guidelines. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
19. A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women.
- Author
-
Davidson, Michael H., Dugan, Lynn D., Davidson, M H, Dugan, L D, Stocki, J, Dicklin, M R, Maki, K C, Coletta, F, Cotter, R, McLeod, M, and Hoersten, K
- Subjects
- *
HYPERCHOLESTEREMIA , *FRUIT juices , *DIETARY fiber , *HEALTH , *NUTRITION , *HYPERCHOLESTEREMIA treatment , *BEVERAGES , *BODY weight , *CHOLESTEROL , *CLINICAL trials , *COMPARATIVE studies , *DIET , *DIETARY supplements , *FRUIT , *RESEARCH methodology , *MEDICAL cooperation , *POLYSACCHARIDES , *RESEARCH , *SOLUBILITY , *VISCOSITY , *EVALUATION research , *RANDOMIZED controlled trials , *THERAPEUTICS - Abstract
This study was designed to determine whether a soluble dietary fiber supplement containing gum arabic and pectin in apple juice would lower serum lipids in 110 hypercholesterolemic men and women. Subjects were stabilized on an American Heart Association Phase I Diet for 8 wk. Those with elevated low density lipoprotein cholesterol levels, despite dietary modification, continued to follow the diet and were randomly assigned to receive 720 mL/d of apple juice containing 0 (control), 5, 9 or 15 g of gum arabic and pectin (4:1 ratio) for 12 wk, followed by a 6-wk apple juice-only washout phase. Serum lipid profiles, body weight and 3-day diet records were collected at 3-wk intervals. No significant differences among groups were observed in serum lipid responses during treatment or washout. During the treatment phase, mean serum total cholesterol and triglyceride concentrations increased by 3.5 and 28.5%, respectively (all groups combined, P < 0.0001). The high density lipoprotein cholesterol level did not change significantly from baseline in any group. During washout, mean total cholesterol concentration rose by an additional 2.4% (P < 0.05) compared with the value at the end of the treatment period, suggesting that the apple juice used to deliver the fiber supplement may have contributed to the adverse changes observed in the serum lipid profile. These findings do not support the hypothesized hypocholesterolemic effect of the gum arabic/pectin (4:1) mixture studied, but do underline the importance of selecting appropriate vehicles for delivery of dietary fiber mixtures. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
20. Combined dyslipidemia with a focus on current and emerging therapeutic approaches.
- Author
-
Davidson, Michael H.
- Subjects
- *
DYSLIPIDEMIA , *DIABETES , *METABOLIC disorders , *BLOOD lipids , *THERAPEUTICS - Abstract
As the population becomes more obese and the prevalence of diabetes and metabolic syndrome increases, lowdensity lipoprotein cholesterol (LDL-C) is increasingly losing its value as a sole predictor for cardiovascular (CV) risk. In addition, targeting LDL-C treatment to <70 mg/dL has achieved significant cardiovascular disease (CVD) benefits but a high residual risk continues, especially if other lipid parameters such as triglycerides (TGs) and highdensity lipoprotein cholesterol (HDL-C) remain abnormal. Identifiable residual risk factors include low HDL-C and HDL-phospholipid, elevated TGs, LDL-phospolipid, apolipoprotein (apo) B, high-sensitivity C-reactive protein (hs- CRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2). Although additional therapeutic intervention beyond statin therapy to modify these residual risk factors have not yet been proved, there is ample evidence that patients with these abnormalities remain at increased risk despite an LDL-C and non-HDL-C at goal (<70 and <100 mg/dL, respectively), according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) 2004 Update. Statin combination therapy with niacin, fibrates, and prescription omega-3 fatty acids provides additional improvements in non-HDL and HDL-C. Clinical trials are underway to evaluate the effects of niacin in combination with a statin on CV outcomes. Cholesteryl ester transfer protein (CETP) inhibitors, which increase HDL-C, are also in late-phase development to potentially address the residual risk for patients with low HDL. [ABSTRACT FROM AUTHOR]
- Published
- 2011
21. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
- Author
-
Jones, Peter H. and Davidson, Michael H.
- Subjects
- *
RHABDOMYOLYSIS , *FENOFIBRATE , *STATINS (Cardiovascular agents) , *THERAPEUTICS - Abstract
There is an increasing trend among physicians to use 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in combination with other antilipidemic agents. The complementary lipid-altering effects of statins and fibric acid derivatives (fibrates) have led to an increasing use of statin/fibrate combination therapy, particularly for patients who have mixed dyslipidemia. Clinical experience indicates that there may be an increased risk of myotoxicity associated with statin/fibrate combination therapy. However, it is not known whether there are differences in the rate of myotoxicity between the use of fenofibrate and gemfibrozil in combination with statins. To evaluate this question, data from the United States Food and Drug Administration''s Adverse Event Reporting System was reviewed to determine how many adverse events were reported for patients who were being treated concomitantly with statins and fibrates. The findings suggest that the use of fenofibrate in combination with statins results in fewer reports of rhabdomyolysis per million prescriptions dispensed than does the use of gemfibrozil. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
22. Coronary Heart Disease: Risk Assessment and Treatment Strategies to Reduce Cardiovascular Events.
- Author
-
Davidson, Michael H., Brown, Alan S., and Toth, Peter P.
- Subjects
- *
CORONARY disease , *THERAPEUTICS - Abstract
A quiz about risk assessment and treatment strategies for coronary heart disease is presented.
- Published
- 2011
23. Possible Differences Between Fibrates in Pharmacokinetic Interactions With Statins.
- Author
-
Ballantyne, Christie M. and Davidson, Michael H.
- Subjects
- *
PHARMACOKINETICS , *STATINS (Cardiovascular agents) , *MUSCLE diseases , *THERAPEUTICS - Abstract
Focuses on possible differences between fibrates in pharmacokinetic interactions with statins. Concerns of physicians about prescribing fibrates and statins concomitantly; Risk of myopathy with statin therapy; Potential differences between fibrates in their ability to affect the glucuronidation pathway.
- Published
- 2003
- Full Text
- View/download PDF
24. Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention
- Author
-
Davidson, Michael H.
- Subjects
- *
NIACIN , *DYSLIPIDEMIA , *THERAPEUTIC complications , *PATIENT education , *PREVENTION , *THERAPEUTICS - Abstract
Niacin, or nicotinic acid, has established efficacy for the treatment of dyslipidemia, but the clinical use of niacin has been limited by cutaneous flushing, a well-recognized associated adverse effect. Flushing has been cited as the major reason for the discontinuation of niacin therapy, estimated at rates as high as 25%–40%. A number of studies have established that moderate doses of prostaglandin inhibitors reduce the cutaneous flushing response from niacin administration. Other strategies for reducing flushing include regular consistent dosing, the use of extended-release formulations, patient education, dosing with meals or at bedtime, and the avoidance of alcohol, hot beverages, spicy foods, and hot baths or showers close to or after dosing. Because niacin has recognized cardiovascular benefits, promoting patient awareness of factors that can minimize niacin-induced flushing can help enhance the tolerability of this valuable dyslipidemic agent. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
25. Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart disease.
- Author
-
Davidson, Michael H.
- Subjects
- *
CORONARY heart disease treatment , *CARDIOVASCULAR diseases , *PATIENTS , *LIPOPROTEINS , *THERAPEUTICS , *CARDIOLOGY , *CLINICAL medicine - Abstract
The article presents an answer to a clinical question related to the comparison of the effectiveness of intensive atorvastatin therapy in patients with coronary heart disease (CHD), with moderate atorvastatin therapy for reducing major cardiovascular events. This study included 10,001 patients 35 to 75 years of age who had clinically evident CHD and low-density lipoprotein. Exclusion criteria included hypersensitivity to statins, active liver disease, pregnancy, and uncontrolled diabetes mellitus.
- Published
- 2005
- Full Text
- View/download PDF
26. Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy
- Author
-
Maki, Kevin C., Dicklin, Mary R., Davidson, Michael H., Doyle, Ralph T., and Ballantyne, Christie M.
- Subjects
- *
LIPID metabolism disorders , *BLOOD cholesterol , *LOW density lipoproteins , *EZETIMIBE , *STATINS (Cardiovascular agents) , *HIGH-omega-3 fatty acid diet , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
The present post hoc analysis of data from the COMBination of prescription Omega-3 with Simvastatin (COMBOS) study investigated the predictors of the low-density lipoprotein (LDL) cholesterol response to prescription omega-3 acid ethyl ester (P-OM3) therapy in men and women with high (200 to 499 mg/dl) triglycerides during diet plus simvastatin therapy. Subjects (n = 256 randomized) received double-blind P-OM3 4 g/day or placebo for 8 weeks combined with diet and open-label simvastatin 40 mg/day. The percentage of changes from baseline (with diet plus simvastatin) in lipids was evaluated by tertiles of baseline LDL cholesterol and triglyceride concentrations. The baseline LDL cholesterol tertile was a significant predictor of the LDL cholesterol response (p = 0.022 for the treatment by baseline tertile interaction). The median LDL cholesterol response in the P-OM3 group was +9.5% (first tertile, <80.4 mg/dl), −0.9% (second tertile), and −6.4% (third tertile, ≥99.0 mg/dl). Non–high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride responses did not vary significantly by baseline LDL cholesterol tertile. The reductions in very-low-density lipoprotein cholesterol concentrations were greater than the increases in LDL cholesterol, where present, resulting in a net decrease in the concentration of cholesterol carried by atherogenic particles (non–high-density lipoprotein cholesterol) in all baseline LDL cholesterol tertiles. In conclusion, these results suggest that the increase in LDL cholesterol that occurred with the addition of P-OM3 to simvastatin therapy in subjects with mixed dyslipidemia was confined predominantly to those with low LDL cholesterol levels while receiving simvastatin monotherapy. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
27. Introduction.
- Author
-
Davidson, Michael H.
- Subjects
- *
STATINS (Cardiovascular agents) , *THERAPEUTICS - Abstract
The article discusses various reports published within the issue including an overview of statin mechanism of action, adverse events and possibilities for combination therapy.
- Published
- 2011
28. A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial).
- Author
-
Maki, Kevin C., Orloff, David G., Nicholls, Stephen J., Dunbar, Richard L., Roth, Eli M., Curcio, Danielle, Johnson, Judith, Kling, Douglas, and Davidson, Michael H.
- Subjects
- *
THERAPEUTIC use of omega-3 fatty acids , *STATINS (Cardiovascular agents) , *ANALYSIS of covariance , *ANALYSIS of variance , *BLOOD testing , *COMBINATION drug therapy , *CHI-squared test , *CONFIDENCE intervals , *DRUG side effects , *LOW density lipoproteins , *RESEARCH funding , *STATISTICS , *TRIGLYCERIDES , *DATA analysis , *RANDOMIZED controlled trials , *BLIND experiment , *DATA analysis software , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background: A novel omega-3 formulation in free fatty acid form (OM3-FFA) has as much as 4-fold greater bioavailability than ethyl ester forms and reduces triglyceride (TG) levels in patients with severe hypertriglyceridemia. Objective: This study was designed to evaluate the efficacy of adding OM3-FFA (2 or 4 g/d) to statin therapy for lowering non-HDL-C and TG levels in subjects with persistent hypertriglyceridemia and at high risk for cardiovascular disease. Methods: In this double-blind, parallel-group study, 647 diet-stable patients with fasting TG levels ≥200 mg/ dL and <500 mg/dL (treated with a maximally tolerated dose of statin or statin with ezetimibe) and at high risk for cardiovascular disease were randomized to 6 weeks of treatment with capsules of control (olive oil [OO]) 4 g/d, OM3-FFA 2 g/d (plus 2 g/d OO), or OM3-FFA 4 g/d. Assessments included fasting serum levels of lipids and apolipoproteins (apo); plasma concentrations of eicosa-pentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, and arachidonic acid; and laboratory safety values and adverse events. Results: In the 627 subjects in the intention to treat sample, non-HDL-C levels were reduced with OM3-FFA 2 g/d and OM3-FFA 4 g/d (-3.9% and -6.9%, respec-tively) compared with OO (-0.9%) (both, P < 0.05), as were TG levels (-14.6% and -20.6%, respectively, vs -5.9%; both, P < 0.001). LDL-C levels increased with OM3-FFA 2 g/d (4.6%) compared with OO (1.1%) (P = 0.025) but not with OM3-FFA 4 g/d (1.3%). Total cholesterol and VLDL-C concentrations were reduced compared with OO with both OM3-FFA dosages, and the total cholesterol/HDL-C ratio and apo AI and apo B levels were significantly lowered with OM3-FFA 4 g/d only (all at least P < 0.05). Percent changes from baseline in HDL-C did not differ between OO and either OM3-FFA group. Plasma concentrations of docosahex-aenoic acid, eicosapentaenoic acid, and docosapentaenoic acid were significantly increased and arachidonic acid was significantly reduced in both OM3-FFA treatment groups compared with the OO responses (all, P < 0.001). Withdrawals related to treatment-emergent adverse events ranged from 0.9% with OO to 3.2% with OM3-FFA 4 g/d. Conclusions: OM3-FFA was well tolerated and low-ered non-HDL-C and TG levels at both 2- and 4-g/d dos-ages in patients with persistent hypertriglyceridemia taking a statin, with the 4-g/d dosage providing incremental im-provements compared with 2 g/d. ClinicalTrials.gov iden-tifier: NCT01408303. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.